Equities

Nexalin Technology Inc

NXL:NAQ

Nexalin Technology Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.68
  • Today's Change-0.02 / -2.86%
  • Shares traded7.38k
  • 1 Year change+78.85%
  • Beta--
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

  • Revenue in USD (TTM)150.16k
  • Net income in USD-5.40m
  • Incorporated2010
  • Employees6.00
  • Location
    Nexalin Technology Inc26072 MERIT CIRCLE, SUITE 106LAGUNA NIGUEL 92653United StatesUSA
  • Phone+1 (949) 260-8090
  • Websitehttps://nexalin.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kelyniam Global Inc517.70k-420.28k4.39m0.00--8.11--8.48-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Encision Inc6.56m-529.29k4.63m22.00--2.49--0.7056-0.045-0.0450.5560.15661.702.107.59298,337.30-13.69-3.03-19.50-4.1349.0051.25-8.06-1.891.01-8.890.1761---10.38-5.64-113.55---9.54--
Hawkeye Systems Inc0.00-578.72k4.79m44.00---------0.093-0.0930.00-0.30060.00-------117.01-314.04-----------195.39---1.49--------52.81------
Nu-Med Plus Inc0.00-112.13k4.87m2.00---------0.0014-0.00140.00-0.00220.00----0.00-471.23-447.69---------------21.34--------3.56------
Reflect Scientific Inc1.73m-53.09k5.05m7.00--2.5765.622.92-0.0006-0.00060.02030.0230.71970.846317.05247,638.60-2.2011.10-2.5913.2158.1962.48-3.0610.005.68--0.00---47.09-6.99-613.46------
ADM Tronics Unlimited Inc3.06m-472.80k5.15m7.00--5.05--1.68-0.007-0.0070.04530.01511.113.725.67---17.14-15.22-29.35-22.0942.8741.15-15.45-18.580.8954--0.3259---19.35-0.3572-810.74------
Biomerica Inc5.41m-5.98m5.33m63.00--0.8091--0.9851-0.3554-0.35540.32180.39180.45662.176.4985,920.63-50.43-44.68-61.13-51.7311.2314.11-110.44-63.822.43--0.00--1.420.810916.27---7.64--
Dror Ortho-Design Inc0.00-5.63m5.35m4.00--3.23-----0.012-0.0120.000.00340.00-------577.48-140.50-1,394.24---------118,188.00----0.00-------1,896.02------
Aethlon Medical, Inc.0.00-11.50m5.53m14.00--0.6351-----3.87-3.870.000.62510.00----0.00-84.49-76.25-98.84-85.78-------2,246.87----0.00---100.00---1.43------
Biotricity Inc12.24m-18.28m5.61m55.00------0.4585-1.74-1.741.18-1.272.121.678.08222,624.00-248.61-269.25----71.8958.93-117.41-258.940.106-0.6408----25.1597.8223.57------
Agape ATP Corp1.38m-2.45m6.39m21.00--1.98--4.64-0.6396-0.63960.35990.83660.44648.2536.6665,621.91-78.78---111.56--64.23---176.47--4.66--0.0225---22.92---24.61------
Nexalin Technology Inc150.16k-5.40m7.20m6.00--3.82--47.94-0.7261-0.72610.02020.17810.04460.167911.5325,026.67-160.37---202.23--82.94---3,598.50--4.89--0.00---91.62---173.80------
Sigyn Therapeutics Inc0.00-3.70m7.27m5.00---------3.08-3.080.00-2.910.00----0.00-1,085.72-493.15-----------10,223.960.0247-2.09---------41.51------
Bioelectronics Corp1.61m-289.82k7.41m9.00------4.60-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Neurometrix Inc4.38m-7.94m8.49m26.00--0.4881--1.94-5.50-5.502.918.580.21021.158.53168,600.80-38.06-23.24-40.80-27.2660.1959.17-181.03-48.8810.71--0.00---28.52-18.18-47.84--5.03--
ALR Technologies Inc9.49k-8.00m9.53m6.00------1,004.43-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Data as of Oct 08 2024. Currency figures normalised to Nexalin Technology Inc's reporting currency: US Dollar USD

Institutional shareholders

1.41%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 30 Jun 202444.06k0.58%
Cadaret, Grant & Co., Inc.as of 30 Jun 202438.41k0.51%
Jane Street Capital LLCas of 31 Mar 202411.31k0.15%
Tower Research Capital LLCas of 31 Mar 20249.08k0.12%
UBS Securities LLCas of 31 Mar 20244.17k0.06%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202444.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.